Skip to content
The Nexus
DossierENTITY

Brian Wolpin

Coverage of Brian Wolpin in the Nexus archive.

Earliest in view: May 18 · 11:00 UTCMost recent: Jun 1 · 20:56 UTC
Co-mentioned in this coverage
daraxonrasibtopic1pancreatic cancertopic1ASCOorganization1STAT+organization1Chicagoplace1Daraxonrasibtopic1Dana-Farber Cancer Instituteorganization1The New England Journal of Medicineorganization1Hale Family Center for Pancreatic Cancer Researchorganization1
Recent coverage
  • HEALTHJun 1 · 20:56 UTCSTAT NEWS
    STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways

    The ASCO meeting highlighted discussions on barriers to cancer care and new treatments, including Brian Wolpin's presentation on the daraxonrasib pancreatic cancer study, which received a sustained standing ovation. The article concludes with a farewell from Chicago and an invitation to a virtual recap.

  • HEALTHMay 18 · 11:00 UTCFOX NEWS
    New pancreatic cancer pill could reshape treatment as early trial results stun researchers

    A new pancreatic cancer pill called Daraxonrasib has shown promise in early testing, with about 30% of patients seeing a positive response and 90% having their cancer either shrink or stop getting worse. The pill is designed to block multiple active cancer signals that help tumor cells grow. The clinical trial was led by the Dana-Farber Cancer Institute.

Brian Wolpin · Dossier · The Nexus